Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Visovatti, Scott H ^a   Hyman, Matthew C ^b   Bouis, Diane ^a   Neubig, Richard ^a   McLaughlin, Vallerie V ^a   Pinsky, David J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; APYRASE; CD39 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOGOLD LABELING; MALE; PATHOGENESIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; THIN LAYER CHROMATOGRAPHY;

ADOLESCENT; ADULT; ANTIGENS, CD; APYRASE; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84863844851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040829     Document Type: Article

References (41)

1. Koziak K, Sevigny J, Robson SC, Siegel JB, Kaczmarek E, (1999) Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb Haemost 82: 1538-1544.
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, et al. (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc. J Am Coll Cardiol 53: 1573-1619 and the Pulmonary Hypertension Association.
3. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M, (2007) A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 30: 1103-1110.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349.
5. Burnstock G, (1972) Purinergic nerves. Pharmacol Rev 24: 509-581.
6. Brook MM, Fineman JR, Bolinger AM, Wong AF, Heymann MA, et al. (1994) Use of ATP-MgCl2 in the evaluation and treatment of children with pulmonary hypertension secondary to congenital heart defects. Circulation 90: 1287-1293.
7. Dawicki DD, Chatterjee D, Wyche J, Rounds S, (1997) Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells. Am J Physiol 273: L485-494.
8. McAuslan BR, Reilly WG, Hannan GN, Gole GA, (1983) Angiogenic factors and their assay: activity of formyl methionyl leucyl phenylalanine, adenosine diphosphate, heparin, copper, and bovine endothelium stimulating factor. Microvasc Res 26: 323-338.
9. Dorsam RT, Kunapuli SP, (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113: 340-345.
10. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, et al. (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314: 1792-1795.
11. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, et al. (1996) Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271: 33116-33122.
12. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, et al. (1997) The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99: 1351-1360.
13. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, et al. (2002) Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 109: 1031-1040.
14. Berchtold S, Ogilvie AL, Bogdan C, Muhl-Zurbes P, Ogilvie A, et al. (1999) Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases. FEBS Lett 458: 424-428.
15. Goepfert C, Imai M, Brouard S, Csizmadia E, Kaczmarek E, et al. (2000) CD39 modulates endothelial cell activation and apoptosis. Mol Med 6: 591-603.
16. Banz Y, Beldi G, Wu Y, Atkinson B, Usheva A, et al. (2008) CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol 142: 627-637.
17. Freyssinet JM, (2003) Cellular microparticles: what are they bad or good for? J Thromb Haemost 1: 1655-1662.
18. Horstman LL, Ahn YS, (1999) Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 30: 111-142.
19. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, et al. (1999) In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 104: 93-102.
20. Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, et al. (2002) Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 30: 450-459.
21. Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, et al. (2005) Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 52: 3337-3348.
22. Yegutkin GG, Samburski SS, Jalkanen S, (2003) Soluble purine-converting enzymes circulate in human blood and regulate extracellular ATP level via counteracting pyrophosphatase and phosphotransfer reactions. FASEB J 17: 1328-1330.
23. Kiffer-Moreira T, Fernandes Sampaio ME, Alviano DS, Axelband F, Cesar GV, et al. (2010) Biochemical characterization of an ecto-ATP diphosphohydrolase activity in Candida parapsilosis and its possible role in adenosine acquisition and pathogenesis. FEMS yeast research 10: 735-746.
24. Wall MJ, Wigmore G, Lopatar J, Frenguelli BG, Dale N, (2008) The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition. Neuropharmacology 55: 1251-1258.
25. Blaustein MP, Juhaszova M, Golovina VA, (1998) The cellular mechanism of action of cardiotonic steroids: a new hypothesis. Clinical and experimental hypertension 20: 691-703.
26. Meyer-Fernandes JR, Dutra PM, Rodrigues CO, Saad-Nehme J, Lopes AH, (1997) Mg-dependent ecto-ATPase activity in Leishmania tropica. Archives of biochemistry and biophysics 341: 40-46.
27. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH, (1993) Recent research on the biological activity of suramin. Pharmacological reviews 45: 177-203.
28. Crack BE, Pollard CE, Beukers MW, Roberts SM, Hunt SF, et al. (1995) Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. British journal of pharmacology 114: 475-481.
29. Muller CE, Iqbal J, Baqi Y, Zimmermann H, Rollich A, et al. (2006) Polyoxometalates-a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. Bioorganic & medicinal chemistry letters 16: 5943-5947.
30. Zebisch M, Strater N, (2007) Characterization of Rat NTPDase1,-2, and-3 ectodomains refolded from bacterial inclusion bodies. Biochemistry 46: 11945-11956.
31. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, et al. (2008) Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 177: 536-543.
32. Bogle RG, Coade SB, Moncada S, Pearson JD, Mann GE, (1991) Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem Biophys Res Commun 180: 926-932.
33. Boeynaems JM, Galand N, (1983) Stimulation of vascular prostacyclin synthesis by extracellular ADP and ATP. Biochem Biophys Res Commun 112: 290-296.
34. Zimmermann H, (1992) 5′-Nucleotidase: molecular structure and functional aspects. Biochem J 285 (Pt 2): 345-365.
35. Edmunds NJ, Marshall JM, (2003) The roles of nitric oxide in dilating proximal and terminal arterioles of skeletal muscle during systemic hypoxia. J Vasc Res 40: 68-76.
36. Bullough DA, Zhang C, Montag A, Mullane KM, Young MA, (1994) Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo. The Journal of clinical investigation 94: 1524-1532.
37. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R, (1983) Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 158: 1160-1177.
38. Dubey RK, Gillespie DG, Mi Z, Jackson EK, (1998) Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension 31: 516-521.
39. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, et al. (2003) Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 1: 2497-2509.
40. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD, (1994) Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 90: 1908-1918.
41. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, et al. (2008) Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med 177: 1268-1275.